Bellemin Jean-Marc 4
4 · IOVANCE BIOTHERAPEUTICS, INC. · Filed Mar 6, 2023
Insider Transaction Report
Form 4
Bellemin Jean-Marc
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2023-03-02+168,750→ 168,750 totalExercise: $7.12Exp: 2033-03-02→ Common Stock (168,750 underlying)
Footnotes (1)
- [F1]Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.